Ncardia
Business Services · Netherlands · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Galileiweg Biopartner Building 1 8, BD L...Phone Number
+31 713322230Website
www.ncardia.comRevenue
$17.2 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
1
1
2
1
1
About Ncardia
Founded in 2000 and headquartered in Belgium, Ncardia brings cell manufacturing and process development expertise to cell therapy by designing and delivering human induced pluripotent stem cell (iPSC) solutions to specification. Their offerings extend from concept development to pre-clinical studies, including custom manufacturing of a range of cell types, as well as discovery services such as disease modelling, screening, and safety assays.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ncardia your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Ncardia had a recent Job posting/layoffs
Check if Ncardia has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ncardia has new funding data
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ncardia launches new products
Congratulate Masked Content for being promoted to Masked Content at Ncardia
Earning: See what the market has to say on Ncardia recently announced quarterly report
Ncardia, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Ncardia is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Ncardia
Find more new buyers
Company Profile Activity
Activity Insights
Ncardia is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ncardia is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ncardia.
Ncardia financials insights
Gather financial insights about Ncardia, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Series A
$4.9M
2017
Series B
$11.8M
Ncardia Tech Stack
A closer look at the technologies used by Ncardia
See more technologies
Most Recent Scoops
Open Position
Open Position
Open Position
Open Position
New Hire
Executive Move
Board of Directors
Ncardia News & Media
Ncardia Launches Ncyte® Microglia to Advance Research in Neurodegenerative Diseases
LEIDEN, Netherlands--(BUSINESS WIRE)--Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® Microglia, a groundbreaking tool to advance research in neurodegenerative diseases and central nervous system (CNS) disorders. Ncyte® Microglia are hiPSC-derived models that closely mimic primary human microglia, exhibiting key functional characteristics such as phagocytosis, cytokine signaling response, and the expression of microglial mNcardia Launches Ncyte® Heart in a Box to Advance Cardiovascular Research and Precision Medicine
LEIDEN, The Netherlands--(BUSINESS WIRE)--Ncardia, a leading human induced pluripotent stem cell (hiPSC) technology company, today announced the launch of Ncyte® Heart in a Box, a breakthrough 3D cardiac microtissue model designed to drive innovation in cardiovascular research and drug discovery. The Ncyte® Heart in a Box system is derived from hiPSCs and integrates three essential cardiac cell types: ventricular cardiomyocytes, endothelial cells, and cardiac fibroblasts. Together, these high-pNeurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Highlights: Positive preclinical results in human in vitro iPSC Motor Neuron models of Amyotrophic Lateral Sclerosis (ALS) Neurizon's lead drug NUZ-001 and its major active metabolite significantly and dose-dependently prevented the aggregation of TAR DNA-binding protein 43 (TDP-43) by...Ncardia Launches Panel of Ready-to-Use Assays to Streamline Screening and Selection of New Therapeutic Candidates
LEIDEN, Netherlands--(BUSINESS WIRE)-- #ALSResearch--Ncardia, a leading human iPSC company, announced today the launch of a new panel of ready-to-use assays designed to streamline the screening and selection of new therapeutic candidates, with a specific focus on neurodegenerative diseases. The new panel features standardized, highly robust, and reproducible assays for Alzheimer's Disease, Parkinson's Disease, ALS/FTD (Amyotrophic Lateral Sclerosis/Frontotemporal Dementia), Neuroinflammation, an
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ncardia
Sign Up For FreeTo access detailed company insights
Founded in 2000 and headquartered in Belgium, Ncardia brings cell manufacturing and process development expertise to cell therapy by designing and delivering human induced pluripotent stem cell (iPSC) solutions to specification. Their offerings extend from concept development to pre-clinical studies, including custom manufacturing of a range of cel... Read More
